Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $41.50

Oculis Holding AG (NASDAQ:OCS) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $41.50.

OCS has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Bank of America dropped their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Chardan Capital restated a “buy” rating and issued a $51.00 target price on shares of Oculis in a research report on Tuesday, November 11th. Finally, HC Wainwright lifted their price target on Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, November 11th.

Oculis Stock Performance

Shares of OCS stock opened at $23.04 on Friday. The company has a market cap of $1.21 billion, a P/E ratio of -9.14 and a beta of 0.31. The business has a 50 day moving average of $20.07 and a two-hundred day moving average of $19.02. Oculis has a 52 week low of $14.00 and a 52 week high of $24.50. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.02.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. As a group, analysts anticipate that Oculis will post -2.09 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in shares of Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares during the period. Aventura Private Wealth LLC bought a new position in Oculis in the 4th quarter valued at about $80,000. Geode Capital Management LLC increased its stake in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after buying an additional 6,384 shares during the period. Compagnie Lombard Odier SCmA increased its stake in Oculis by 11.5% during the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock valued at $1,883,000 after buying an additional 10,000 shares during the period. Finally, Bosun Asset Management LLC bought a new stake in shares of Oculis during the 2nd quarter worth about $378,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.